{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:21:21Z","timestamp":1792714881280,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10875-019-0592-5","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T21:02:56Z","timestamp":1547499776000},"page":"159-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Federica","family":"Pulvirenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Crescenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Fabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tabolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-7584","authenticated-orcid":false,"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"592_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","volume":"4","author":"FA Bonilla","year":"2016","unstructured":"Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38\u201359.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"592_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fimmu.2015.00436","volume":"6","author":"A Farrugia","year":"2015","unstructured":"Farrugia A, Visentini M, Quinti I. Editorial: immunoglobulin therapy in the 21st century\u2014the dark side of the moon. Front Immunol. 2015;6:436.","journal-title":"Front Immunol"},{"key":"592_CR3","first-page":"40","volume":"11","author":"I Quinti","year":"2013","unstructured":"Quinti I, Coluzzi S, Pulvirenti F, Prezzo A, Girelli G. Polyvalent immunoglobulins: challenges and perspectives. Blood Transfus. 2013;11:40.","journal-title":"Blood Transfus"},{"key":"592_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2014.00665","volume":"5","author":"A Farrugia","year":"2014","unstructured":"Farrugia A, Quinti I. Manufacture of immunoglobulin products for patients with primary antibody deficiencies\u2014the effect of processing conditions on product safety and efficacy. Front Immunol. 2014;5:665.","journal-title":"Front Immunol"},{"key":"592_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","volume":"5","author":"J Kerr","year":"2014","unstructured":"Kerr J, Quinti I, Eibl M, Chapel H, Sp\u00e4th PJ, Sewell WA, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014;5:629.","journal-title":"Front Immunol"},{"key":"592_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/PPA.S60771","volume":"8","author":"T Espanol","year":"2014","unstructured":"Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621\u20139. \n                    https:\/\/doi.org\/10.2147\/PPA.S60771\n                    \n                  .","journal-title":"Patient Prefer Adherence"},{"key":"592_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10875-015-0196-7","volume":"35","author":"FO Seeborg","year":"2015","unstructured":"Seeborg FO, Seay R, Boyle M, Boyle J, Scalchunes C, Orange JS. Perceived health in patients with primary immune deficiency. J Clin Immunol. 2015;35:638\u201350.","journal-title":"J Clin Immunol"},{"key":"592_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3349\/ymj.2012.53.3.603","volume":"53","author":"I Quinti","year":"2012","unstructured":"Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J. 2012;53:603\u201310. \n                    https:\/\/doi.org\/10.3349\/ymj.2012.53.3.603\n                    \n                  .","journal-title":"Yonsei Med J"},{"key":"592_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fimmu.2014.00605","volume":"5","author":"S Tabolli","year":"2014","unstructured":"Tabolli S, Giannantoni P, Pulvirenti F, La Marra F, Granata G, Milito C, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol. 2014;5:605.","journal-title":"Front Immunol"},{"key":"592_CR10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2016.07.012","volume":"4","author":"I Quinti","year":"2016","unstructured":"Quinti I, Pulvirenti F, Giannantoni P, Hajjar J, Canter DL, Milito C, et al. Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL questionnaire. J Allergy Clin Immunol Pract. 2016;4:1169\u201379.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"592_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fimmu.2018.01308","volume":"9","author":"GL Jones","year":"2018","unstructured":"Jones GL, Vogt KS, Chambers D, Clowes M, Shrimpton A. What is the burden of immunoglobulin replacement therapy in adult patients with primary Immunodeficiencies? A systematic review. Front Immunol. 2018;9:1308. \n                    https:\/\/doi.org\/10.3389\/fimmu.2018.01308\n                    \n                  .","journal-title":"Front Immunol"},{"key":"592_CR12","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1111\/jocn.14580","volume":"27","author":"C Petersson","year":"2018","unstructured":"Petersson C, Fust R, Hagstedt C, W\u00e5gstr\u00f6m P, Nilsdotter-Augustinsson \u00c5. \u201cExperiences of the burden of treatment\u201d\u2014patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency. J Clin Nurs. 2018;27:4270\u20138. \n                    https:\/\/doi.org\/10.1111\/jocn.14580\n                    \n                  .","journal-title":"J Clin Nurs"},{"key":"592_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","volume":"179","author":"S Jolles","year":"2015","unstructured":"Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146\u201360. \n                    https:\/\/doi.org\/10.1111\/cei.12485\n                    \n                  .","journal-title":"Clin Exp Immunol"},{"key":"592_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188:333\u201341. \n                    https:\/\/doi.org\/10.1111\/cei.12915\n                    \n                  .","journal-title":"Clin Exp Immunol"},{"key":"592_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10875-014-0081-9","volume":"34","author":"C Milito","year":"2014","unstructured":"Milito C, Pulvirenti F, Pesce AM, Digiulio MA, Pandolfi F, Visentini M, et al. Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies. J Clin Immunol. 2014;34:813\u20139. \n                    https:\/\/doi.org\/10.1007\/s10875-014-0081-9\n                    \n                  .","journal-title":"J Clin Immunol"},{"key":"592_CR16","unstructured":"Treatment experiences and preferences of patients with primary immune deficiency diseases: 2008 national survey of patients. Available at: \n                    http:\/\/wwwprimaryimmune.org\/survey_research\/surveys.htm\n                    \n                  ."},{"issue":"7","key":"592_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10875-017-0428-0","volume":"37","author":"I Quinti","year":"2017","unstructured":"Quinti I, Pulvirenti F. Health-related quality of life and patients\u2019 empowerment in the health care of primary immune deficiencies. J Clin Immunol. 2017;37(7):615\u20136.","journal-title":"J Clin Immunol"},{"key":"592_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1468-3083.2001.00336.x","volume":"15","author":"D Picardi","year":"2001","unstructured":"Picardi D, Abeni P, Pasquini A. Assessing psychological distress in patients with skin diseases: reliability, validity and factor structure of the GHQ-12. J Eur Acad Dermatol Venereol. 2001;15:410\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"592_CR19","unstructured":"Recommendations for diagnosis and treatment of common variable immunedeficiency by italian primary immunodeficiecies network (IPINET), 2001. Available at: \n                    www.aieop.org\/stdoc\/raccomandazioni\/racc_cvid_2001.doc\n                    \n                  ."},{"key":"592_CR20","unstructured":"Agency for Healthcare Research and Quality. The six domains of health care quality. Rockville, MD2017 [Available from: \n                    http:\/\/www.ahrq.gov\/professionals\/quality-patient-safety\/talkingquality\/create\/sixdomains.html\n                    \n                  ]."},{"key":"592_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","volume":"36","author":"J Routes","year":"2016","unstructured":"Routes J, Costa-Carvalho BT, Grimbacher B, Paris K, Ochs HD, Filipovich A, et al. Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment. J Clin Immunol. 2016;36:450\u201361.","journal-title":"J Clin Immunol"},{"key":"592_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1081-1206(10)61469-X","volume":"93","author":"H Tcheurekdjian","year":"2004","unstructured":"Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol. 2004;93:160\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"592_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10875-017-0404-8","volume":"37","author":"NL Rider","year":"2017","unstructured":"Rider NL, Kutac C, Hajjar J, Scalchunes FO, Seeborg C, Boyle M, et al. Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment. J Clin Immunol. 2017;37:461\u201375.","journal-title":"J Clin Immunol"},{"key":"592_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.jaci.2016.11.029","volume":"139","author":"M Ballow","year":"2017","unstructured":"Ballow M, Conaway MR, Sriaroon P, Rachid RA, Seeborg FO, Duff CM, et al. Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). J Allergy Clin Immunol. 2017;139:2007\u201310.","journal-title":"J Allergy Clin Immunol"},{"key":"592_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13223-015-0092-y","volume":"11","author":"F Jiang","year":"2015","unstructured":"Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"592_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","volume":"112","author":"H Chapel","year":"2008","unstructured":"Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277\u201386. \n                    https:\/\/doi.org\/10.1182\/blood-2007-11-124545\n                    \n                  .","journal-title":"Blood"},{"key":"592_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11606-017-4117-8","volume":"32","author":"G Spencer-Bonilla","year":"2017","unstructured":"Spencer-Bonilla G, Qui\u00f1ones AR, Montori VM. International minimally disruptive medicine workgroup. Assessing the burden of treatment. J Gen Intern Med. 2017;32:1141\u20135. \n                    https:\/\/doi.org\/10.1007\/s11606-017-4117-8.","journal-title":"J Gen Intern Med"},{"key":"592_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0356-x","volume":"13","author":"VT Tran","year":"2015","unstructured":"Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. BMC Med. 2015;13:115. \n                    https:\/\/doi.org\/10.1186\/s12916-015-0356-x\n                    \n                  .","journal-title":"BMC Med"},{"key":"592_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94\u2013100.","journal-title":"J Clin Immunol"},{"key":"592_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/PPA.S87271","volume":"9","author":"J-f Jin","year":"2015","unstructured":"Jin J-f, Zhu L-l, Chen M, Hui-min X, Wang H-f, Feng X-q, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923\u201342. \n                    https:\/\/doi.org\/10.2147\/PPA.S87271\n                    \n                  .","journal-title":"Patient Prefer Adherence"},{"key":"592_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.15761\/CCRR.1000149","volume":"1","author":"SN Shah","year":"2015","unstructured":"Shah SN, Todoric K, Tarrant TK. Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease. Clin Case Rep Rev. 2015 Jul 28;1:151\u20132.","journal-title":"Clin Case Rep Rev"},{"key":"592_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/imt-2017-0092","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9:1035\u201350. \n                    https:\/\/doi.org\/10.2217\/imt-2017-0092\n                    \n                  .","journal-title":"Immunotherapy"},{"key":"592_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","volume":"73","author":"J Lingman-Framme","year":"2013","unstructured":"Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73:1307\u201319.","journal-title":"Drugs"},{"key":"592_CR34","doi-asserted-by":"crossref","unstructured":"Ataeinia B, Montazeri A, Tavakol M, Azizi G, Kiaee F, Tavakolinia N, et al. Measurement of health-related quality of life in primary antibody-deficient patients. Immunol Investig. 2017:1\u201312.","DOI":"10.1080\/08820139.2016.1258710"},{"key":"592_CR35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","volume":"103","author":"M Berger","year":"2010","unstructured":"Berger M, Murphy E, Riley P, Bergman GE, Investigators VT. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103:856\u201363.","journal-title":"South Med J"},{"key":"592_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","volume":"35","author":"A Vultaggio","year":"2015","unstructured":"Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO Prospective Multicenter Study. Clin Drug Investig. 2015;35:179\u201385.","journal-title":"Clin Drug Investig"},{"key":"592_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","volume":"126","author":"A Gardulf","year":"2008","unstructured":"Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study G. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126:81\u20138.","journal-title":"Clin Immunol"},{"key":"592_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jaip.2016.09.014","volume":"4","author":"DC Adelman","year":"2016","unstructured":"Adelman DC, Howard K. Assessing quality of life in patients with common variable immunodeficiency: why it matters. J Allergy Clin Immunol Pract. 2016;4:1180\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"592_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fimmu.2018.01308","volume":"9","author":"GL Jones","year":"2018","unstructured":"Jones GL, Vogt KS, Chambers D, Clowes M, Shrimpton A. What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A systematic review. Front Immunol. 2018;9:1308.","journal-title":"Front Immunol"},{"key":"592_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","volume":"345","author":"A Gardulf","year":"1995","unstructured":"Gardulf A, Andersen V, Bj\u00f6rkander J, Ericson D, Fr\u00f8land SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365\u20139.","journal-title":"Lancet"},{"key":"592_CR41","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.clinthera.2014.08.007","volume":"36","author":"A Igarashi","year":"2014","unstructured":"Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Clin Ther. 2014;36:1616\u201324.","journal-title":"Clin Ther"},{"key":"592_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","volume":"6","author":"B H\u00f6gy","year":"2005","unstructured":"H\u00f6gy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6:24\u20139.","journal-title":"Eur J Health Econ"},{"key":"592_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s10875-006-9031-5","volume":"26","author":"JM Kittner","year":"2006","unstructured":"Kittner JM, Grimbacher B, Wulff W, J\u00e4ger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400\u20135.","journal-title":"J Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-019-0592-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-019-0592-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-019-0592-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T19:21:25Z","timestamp":1579029685000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-019-0592-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s10875-019-0592-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]},"assertion":[{"value":"6 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"IQ receipt of consultation fees and grants by Shire, CSL Behring, Octapharma, and Kedrion; CA receipt of consultation fees by Shire, Roche, CSL Behring, Octapharma, and Novartis. AF provides compensated consultancy services to manufacturers of immunoglobulin therapies. FP, CM, LB, MC, GF, LC, GS, AP, RN, ST, and FC declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}